Merus
Utrecht, NL · 209 employees on LinkedIn · 4 known investors
Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications. The company's lead candidate, petosemtamab, is in clinical development for head and neck cancer and colorectal cancer.
Founders & leadership
TL
Ton LogtenbergFounder
MT
Mark ThrosbyExecutive
HL
Hui LiuExecutive
JC
John CrowleyExecutive
LA
L. Andres SirulnikExecutive
LB
Lex BakkerExecutive
Board
LM
Lionel M.S. CarnotBoard director
AM
Anand MehraBoard director
JP
John P. de KoningBoard director
GD
Gregory D. PerryBoard director
MT
Mark T. IwickiBoard director
WB
Wolfgang BertholdBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$150.8M disclosed across 3 rounds · 2017–2018
▶$15MraisedJan 2019 · 1 investors · BiotechnologyRule 506(b)
▶$15MraisedJan 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ton LogtenbergExecutive Officer, Director
- Gregory D. PerryDirector
- Lex BakkerExecutive Officer
- Anand MehraDirector
- Mark ThrosbyExecutive Officer
- Russell GreigDirector
- Mark T. IwickiDirector
- John De KruifExecutive Officer
- John P. de KoningDirector
- Len KanavyDirector
- Hui LiuExecutive Officer
- L. Andres SirulnikExecutive Officer
- Peter SilvermanExecutive Officer
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Dec 2018
- Incorporated
- Other, Netherlands
- Federal exemptions
- 06b
▶$55.8MraisedFeb 2018 · 9 investors · BiotechnologyRule 506(b)
▶$55.8MraisedFeb 2018 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark ThrosbyExecutive Officer
- Gregory D. PerryDirector
- Mark T. IwickiDirector
- Lionel M.S. CarnotDirector
- Hui LiuExecutive Officer
- Wolfgang BertholdDirector
- Anand MehraDirector
- John CrowleyExecutive Officer
- John P. de KoningDirector
- L. Andres SirulnikExecutive Officer
- Ton LogtenbergExecutive Officer, Director
- Lex BakkerExecutive Officer
- Offering amount
- $55.8M
- Amount sold
- $55.8M
- First sale
- Feb 2018
- Incorporated
- Other, Netherlands
- Federal exemptions
- 06b
▶$80MraisedJan 2017 · 1 investors · BiotechnologyRule 506(b)
▶$80MraisedJan 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anand MehraDirector
- Wolfgang BertholdDirector
- Shelley MargetsonExecutive Officer
- Mark T. IwickiDirector
- Gregory D. PerryDirector
- Jack B. NielsenDirector
- Lionel M.S. CarnotDirector
- Ton LogtenbergExecutive Officer
- John P. de KoningDirector
- Offering amount
- $80M
- Amount sold
- $80M
- First sale
- Jan 2017
- Incorporated
- Other, Netherlands
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapGlobaldata23 shared keywordsGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.
Agenus21 shared keywords
Companies competing with Merus for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Merus do?
- Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications. The company's lead candidate, petosemtamab, is in clinical development for head and neck cancer and colorectal cancer.
- Who founded Merus?
- Merus was founded by Ton Logtenberg.
- Who are Merus's investors?
- Merus's investors include Avoro Capital Advisors, Pfizer Venture Investments, RA Capital, Sofinnova Ventures.
- How much funding has Merus raised?
- Merus has disclosed $150.8M raised across 3 rounds.
- Where is Merus headquartered?
- Merus is headquartered in Utrecht, NL.